Kincell Bio Introduces Mark R. Bamforth as CEO
Kincell Bio is thrilled to announce the appointment of Mark R. Bamforth as its new Chief Executive Officer (CEO). With a wealth of experience in the biopharmaceutical sector, Mark is set to drive the company’s mission forward in the dynamic cell therapy landscape.
Bringing Valuable Expertise to Kincell Bio
Mark comes to Kincell Bio after serving as the Chair of the Board. His extensive background includes founding and leading three successful Contract Development and Manufacturing Organizations (CDMOs): Arranta Bio, Brammer Bio, and Gallus Bio. Throughout his career, he has demonstrated a remarkable ability to form strong partnerships and to lead initiatives that align with client needs.
Impact of Mark's Leadership
With over two decades at Genzyme Corp., where he led the global operations team with multiple modalities, Mark’s strategic mindset will be instrumental in advancing Kincell Bio’s position in the market. His arrival marks a significant step toward fulfilling the company's ambition of providing high-quality, innovative solutions.
Support from the Executive Team
Bruce Thompson, PhD, will retain his role as Chief Technology Officer (CTO), continuing to enhance Kincell Bio's technical leadership. His focus will be on internal process and analytical development, specifically in modalities such as allogeneic therapies and stem cell products. Bruce’s partnership with the talented team at Kincell Bio is expected to streamline and strengthen development efforts.
Collaborative Vision
Mark expressed enthusiasm about collaborating with Bruce and the rest of the Kincell team. He emphasized the importance of building on the solid foundation already established and expanding the cell therapy CDMO business. His goal is to address the needs of both innovative biotech firms and larger, Fortune 500-backed companies that strive to find solutions for pressing patient-care challenges.
Commitment to Innovation and Development
At Kincell Bio, the focus remains on delivering industry-leading process and analytical development services, as well as cGMP manufacturing capabilities for both early and late-stage clinical development. This dedication ensures that biotech and pharmaceutical companies can efficiently bring their therapies to market.
Kincell Bio’s Mission and Future Goals
Kincell Bio is committed to engineering cells into therapies, with facilities located in Research Triangle Park and Gainesville. The organization's mission includes streamlining CMC development through its expertise in analytical and process development, alongside proven GMP manufacturing, testing, and release capabilities.
Innovative Therapy Solutions
The company supports a variety of innovative cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs. Additionally, Kincell is expanding its knowledge and offerings in stem cell products and induced pluripotent stem cells (iPSCs), further solidifying its role in the evolving field of cell therapy.
Frequently Asked Questions
Who is Mark R. Bamforth?
Mark R. Bamforth is the newly appointed CEO of Kincell Bio, previously serving as the Chair of the Board.
What is the mission of Kincell Bio?
Kincell Bio's mission is to develop high-quality cell therapies, enhancing the efficiency and effectiveness of bringing innovative solutions to the market.
What experience does Mark bring to the role?
Mark has decades of experience in the biopharmaceutical industry, including the founding of three successful CDMOs and leadership roles at Genzyme Corp.
What roles will Bruce Thompson play at Kincell Bio?
Bruce Thompson will continue to serve as the CTO, leading technical development and strengthening the company’s analytical capabilities.
Where are Kincell Bio’s manufacturing facilities located?
Kincell Bio operates manufacturing facilities in Research Triangle Park, NC, and Gainesville, FL.
